• Skip to primary navigation
  • Skip to main content
SRI logo
  • About
    • Press room
    • Our history
  • Expertise
    • Advanced imaging systems
    • Artificial intelligence
    • Biomedical R&D services
    • Biomedical sciences
    • Computer vision
    • Cyber & formal methods
    • Education and learning
    • Innovation strategy and policy
    • National security
    • Ocean & space
    • Quantum
    • QED-C
    • Robotics, sensors & devices
    • Speech & natural language
    • Video test & measurement
  • Ventures
  • NSIC
  • Careers
  • Contact
  • 日本支社
Search
Close
Bios September 8, 2021

Jia-Hwa Fang

Director, Clinical Manufacturing, Pharmaceutical Sciences

Jia-Hwa Fang, Ph.D., leads a team in scale up and clinical manufacturing of early-stage clinical trial materials (CTM) in compliance with current Good Manufacturing Practices (cGMP).

Fang has a broad range of expertise in process development and manufacture of small molecules and biologics for drug products such as parenterals, tablets, capsules, transdermals, suspensions, and topicals. He has extensive experience in all phases of clinical manufacturing, including process troubleshooting, and validation. He has also worked in technology and manufacturing process transfer for late-stage products.

Fang has more than 20 years of industry experience at small and large biotech companies. Prior to joining SRI, Fang was a consultant for Impax Laboratories, Inc. Previously, he was director of formulation and manufacturing at CMC Technology Management Group, and was responsible for formulation and manufacturing at APT Pharmaceuticals. Earlier, he was a senior scientist at Novartis, Chiron Corporation, and TheraTech Inc. He has successfully developed and manufactured microparticles under aseptic conditions for clinical trials, a proprietary adjuvant manufacturing process for Fluad® vaccine, and transdermal formulation for Theraderm®.

He has authored and reviewed regulatory documentation and submissions such as manufacturing and validation protocols and chemistry, manufacturing, and controls (CMC) sections for investigational new drug (IND) and new drug application (NDA) filings in the U.S. and European Medicines Agency (EMA) filings in Europe.

Fang’s Ph.D. in chemistry is from the Missouri University of Science and Technology. He completed a postdoctoral fellowship at Clarkson University, where he developed and transferred a process for the manufacturing of perfluorohydrocarbon blood substitute emulsions.

How can we help?

Once you hit send…

We’ll match your inquiry to the person who can best help you.

Expect a response within 48 hours.

Career call to action image

Make your own mark.

Search jobs

Our work

Case studies

Publications

Timeline of innovation

Areas of expertise

Institute

Leadership

Press room

Media inquiries

Compliance

Careers

Job listings

Contact

SRI Ventures

Our locations

Headquarters

333 Ravenswood Ave
Menlo Park, CA 94025 USA

+1 (650) 859-2000

Subscribe to our newsletter


日本支社
SRI International
  • Contact us
  • Privacy Policy
  • Cookies
  • DMCA
  • Copyright © 2022 SRI International